Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 2Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mastocytosis 1Liver Neoplasms 1Gastroenteropancreatic Neuroendocrine Tumors 1GATA2 Deficiency 1Colorectal Neoplasms 1Advanced Solid Tumor 1

Interventions

Sorafenib 3lenvatinib 2sintilimab 1pembrolizumab 1halofantrine 1glucose-regulated proteins 1camrelizumab 1Tranexamic Acid 1Thalidomide 1Sunitinib 1Standard of Care 1Saline Solution 1Oxaliplatin 1Nadroparin 1Lidocaine 1Injections 1Immune Checkpoint Inhibitors 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Folfox protocol 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Liver Neoplasms × Injections × Clear all
NCT00034333 2005-06-24

Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer

FeRx

Phase 2/3 Terminated
240 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡